**Table e-1. Demographics and clinical features of the patients to whom the COVID-19 questionnaire was emailed, as of May 21, 2020**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Responders****(n = 407)** | **Non-responders****(n = 179)** | ***p* Value** |
| **Female, n (%)** | 273 (67.1) | 127 (71) | 0.353 |
| **Age at survey, y, median (range)** | 48 (19-86) | 51 (20-84) | 0.053 |
| **MS type, n (%)****RRMS****SPMS****PPMS****CIS** | 341 (83.7)36 (8.8)25 (6.1)5 (1.3) | 129 (72.1)25 (13.9)23 (12.8)2 (1.1) | 0.007 |
| **Disease duration, y , mean (SD)** | 15.1 (9.6) | 15.3 (10) | 0.807 |
| **Annualized relapse rate, mean (SD)** | 0.4 (0.6) | 0.3 (0.3) | 0.082 |
| **Last EDSS score, median (range)** | 2.0 (0-8.0) | 2.0 (0-8.5) | 0.029 |
| **Disease modifying treatment, n (%)****Interferon beta****Glatiramer acetate****Dimethylfumarate****Teriflunomide****Ocrelizumab****Rituximab****Ofatumumab****Natalizumab****Fingolimod****Alemtuzumab****Cladribine****Ponesimod****Azathioprine** | 304 (74.7)66 (21.6)41 (13.4)60 (19.6)35 (11.4)13 (4.3)21 (6.9)2 (0.7)15 (4.9)36 (11.8)5 (1.6)7 (2.3)2 (0.7)1 (0.3) | 104 (58.1)24 (23.1)26 (25.0)14 (13.5)12 (11.5)5 (4.8)12 (11.5)0011 (10.6)0000 | <0.0010.067 |